Ryuya Edahiro

Ryuya Edahiro

Auto-generated profile, based on publicly available information

Ryuya Edahiro

Department of Statistical Genetics, Graduate School of Medicine, The University of Osaka, Suita, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2019 in PLOS ONE
Verified
Journal Article
Open access
RERyuya Edahiro
Ryuya Edahiro
MKMasaki Kanazu
Masaki Kanazu
HKHiroyuki Kurebe
Hiroyuki Kurebe
MMMasahide Mori
Masahide Mori
DFDaichi Fujimoto
Daichi Fujimoto
MTMotohiro Tamiya
Motohiro Tamiya
Pembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with a programed death ligand-1 (PD-L1) expression ≥50%. However, the association between the efficacy of pembrolizumab and PD-L1 expression levels in patients with PD-L1 expression ≥50% has not been fully elucidated. We retrospectively analyzed patients with advanced NSCLC and a PD-L1 tumor proportion score (TPS) of ≥50% who received pembrolizumab as a first-line therapy at 11 institutions in Japan between February 2017 and January 2018. Patients were divided into TPS 50-89% and TPS 90-100% (ultra-high PD-L1 expression) cohorts. In total, 149 patients were included: 99 (66.4%) and 50 (33.6%) patients were in the TPS 50-89% and TPS 90-100% cohorts, respectively. Baseline characteristics were similar between the TPS 90-100% and TPS 50-89% cohorts. The objective response rates (ORR) in the TPS 90-100% and TPS 50-89% cohorts were 58.0% and 46.5%, respectively (p = 0.23). Time to treatment failure (TTF) was longer in the TPS 90-100% cohort than in the TPS 50-89% cohort (hazard ratio [HR]: 0.67, 95% confidence interval (CI): 0.42-1.07; p = 0.09). Although TTF within 120 days after the initiation of pembrolizumab therapy was comparable between both cohorts (p = 0.54), TTF after 120 days was significantly longer in the TPS 90-100% cohort than in the TPS 50-89% cohort (HR: 0.22, 95% CI: 0.06-0.87; p = 0.031). Immune related adverse events of grade 3 or more occurred in 16.0% and 19.2% of patients in the TPS 90-100% and TPS 50-89% cohorts, respectively. The patients with an ultra-high PD-L1 expression continued pembrolizumab therapy longer, driven by a reduced risk of treatment failure in the late phase. PD-L1 expression levels might be a predictive biomarker of a first-line immunotherapy benefit in the late phase among NSCLC patients with TPS ≥50%.

9 April 2019 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
RERyuya Edahiro
Ryuya Edahiro
MIMikako Ishijima
Mikako Ishijima
HKHiroyuki Kurebe
Hiroyuki Kurebe
KNKohei Nishida
Kohei Nishida
TUTakeshi Uenami
Takeshi Uenami
MMMasahide Mori
Masahide Mori
A 61‐year‐old woman with stage IVA lung adenocarcinoma exhibited high PD‐L1 expression. Pembrolizumab was administered as second‐line therapy. She developed destructive thyroiditis and her thyroid function started to decline during the administration of three to five courses. She was subsequently diagnosed with fulminant type 1 diabetes mellitus and ketoacidosis during the eighth course and insulin treatment was initiated. Pembrolizumab remained effective and was continued for 21 courses, even after the onset of diabetes mellitus. Immune‐checkpoint inhibitor treatment can be continued with hormone replacement even after the development of type 1 diabetes mellitus as an immune‐related adverse event.

28 January 2026 in Nature
Verified
Journal Article
Open access
PDF file
SNShinichi Namba
Shinichi Namba
KSKyuto Sonehara
Kyuto Sonehara
YKYuriko N. Koyanagi
Yuriko N. Koyanagi
TKTakezo Kikuchi
Takezo Kikuchi
TOTakafumi Ojima
Takafumi Ojima
YOYukinori Okada
Yukinori Okada
Environmental differences in genetic effect sizes, namely, gene–environment interactions, may uncover the genetic encoding of phenotypic plasticity1,2,3. We provide a cross-population atlas of gene–environment interactions comprising 440,210 individuals from European and Japanese populations, with replication in 539,794 individuals from diverse populations. By decomposing the contributions from age, sex and lifestyles, we delineate the aetiology of these gene–environment interactions, including a reverse-causality from a disease-related dietary change. Genome-wide analyses uncovered missing heritability and trait–trait relationships connected by the synergistic effects of genome and environments, which systematically affected polygenic prediction accuracy and cross-population portability. Single-cell projection revealed aging shift of pathways and cell types responsible for genetic regulation. Omics-level gene–environment analyses identified multiple sex-discordant genetic effects in lipid metabolism, informing clinical trial failures for genetically supported drug development. Our comprehensive gene–environment study decodes the dynamics of genetic associations, offering insights into complex trait biology, personalized medicine and drug development.

28 July 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RERyuya Edahiro
Ryuya Edahiro
GSGo Sato
Go Sato
TNTatsuhiko Naito
Tatsuhiko Naito
YSYuya Shirai
Yuya Shirai
RSRyunosuke Saiki
Ryunosuke Saiki
YOYukinori Okada
Yukinori Okada
Current molecular quantitative trait locus catalogs are mostly at bulk resolution and centered on Europeans. Here, we constructed an immune cell atlas with single-cell transcriptomics of >1.5 million peripheral blood mononuclear cells, host genetics, plasma proteomics and gut metagenomics from 235 Japanese persons, including patients with coronavirus disease 2019 (COVID-19) and healthy individuals. We mapped germline genetic effects on gene expression within immune cell types and across cell states. We elucidated cell type- and context-specific human leukocyte antigen (HLA) and genome-wide associations with T and B cell receptor repertoires. Colocalization using dynamic genetic regulation provided better understanding of genome-wide association signals. Differential gene and protein expression analyses depicted cell type- and context-specific effects of polygenic risks. Various somatic mutations including mosaic chromosomal alterations, loss of Y chromosome and mitochondrial DNA (mtDNA) heteroplasmy were projected into single-cell resolution. We identified immune features specific to somatically mutated cells. Overall, immune cells are dynamically regulated in a cell state-dependent manner characterized with multiomic profiles.

Verified
Journal Article
Open access
PDF file
MNMaiko Naito
Maiko Naito
YTYoshito Takeda
Yoshito Takeda
RERyuya Edahiro
Ryuya Edahiro
YSYuya Shirai
Yuya Shirai
TETakatoshi Enomoto
Takatoshi Enomoto
AKAtsushi Kumanogoh
Atsushi Kumanogoh
Nontuberculous mycobacterial pulmonary disease (NTM-PD), mainly caused by Mycobacterium avium complex (MAC), and pulmonary tuberculosis (TB) are emerging health problems worldwide. However, because their clinical features are often similar, it remains difficult to differentiate NTM-PD from TB when the diagnosis cannot be made by sputum culture. To investigate potential serum biomarkers, we conducted non-targeted proteome analysis on serum extracellular vesicles (EVs) collected from 10 patients with MAC pulmonary disease (MAC-PD), 7 patients with TB, and 10 healthy controls. A total of 2614 proteins were identified in the discovery cohort. The EV protein signature from patients with NTM-PD and TB reflected infectious diseases and inflammatory response pathways. Among the identified proteins, the expression of Na+/H+ exchanger regulatory factor 2 (NHERF2) was significantly elevated in patients with MAC-PD compared with healthy controls and patients with TB. Moreover, upregulation of NHERF2 was confirmed by immunoblotting of serum EVs and immunohistochemistry of lungs with mycobacterial infection. Our findings highlight that NHERF2 in serum EVs might be a potential biomarker for distinguishing MAC-PD from TB, possibly reflecting the pathogenesis of MAC-PD.

23 February 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
GSGo Sato
Go Sato
YYYuji Yamamoto
Yuji Yamamoto
KSKyuto Sonehara
Kyuto Sonehara
RSRyunosuke Saiki
Ryunosuke Saiki
TOTakafumi Ojima
Takafumi Ojima
TPThe Biobank Japan Project
The Biobank Japan Project
Our understanding of the biological role of the Y chromosome remains limited. Here, we systematically profile germline Y haplogroups and somatic loss of the Y chromosome (LOY) in 122,683 East Asian males from BioBank Japan and 181,472 European males from the UK Biobank. A phenome-wide scan uncovers male-specific genetic regulation of complex traits, including pleiotropic effects of the Japanese-specific haplogroup D on height and type 2 diabetes (T2D). LOY increases T2D risk in East Asians but is associated with reduced T2D risk in Europeans. In East Asians, LOY contributes to T2D incidence particularly among males with lower polygenic risk scores, providing a compensatory explanation for disease risk beyond germline genetics. Incorporating sex-chromosome variation improves polygenic prediction of T2D risk in both sexes. Single-cell analyses reveal cell type-specific accumulation of LOY across tissues and disease contexts, with LOY in pancreatic β cells potentially impairing glucose metabolism. Our study demonstrates the clinical relevance of Y chromosome variation for diabetes risk prediction and management.